Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Moody's Corporation (MCO) Price & Performance

ADMA Biologics IncTrade
Moody's CorporationTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Moody's Corporation — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.22B), while Moody's Corporation trades at $475 (market cap $82.52B). The key difference: Moody's Corporation is far larger — about 37.2× ADMA Biologics Inc's market cap, and Moody's Corporation pays a 0.86% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMAMCO
Market Cap
$2.22B$82.52B
Sector
HealthFinancials
52-Week High
$20.38$539.61
52-Week Low
$7.60$412.23
Enterprise Value
$2.29B$88.54B
Dividend Yield
0.86%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Moody's Corporation

Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.

Read more on MCO